Moffitt Experts Share Latest Blood Cancer Advancements at ASH Annual Meeting

image of blood cells with words 66th Annual ASH Meeting

The American Society of Hematology (ASH) Annual Meeting and Exposition is the world’s largest event in the field of hematology. It brings together thousands of experts to discuss cutting-edge research and treatment advances in blood disorders and cancers. This year's meeting will showcase groundbreaking studies and clinical trials that promise to shape the future of hematological care.

Moffitt Cancer Center had a strong presence at the conference, presenting over 55 abstracts covering a wide range of topics in blood cancer research. Highlights include promising results from novel therapies like a T-cell engager for diffuse large B-cell lymphoma and new insights into why some cases of multiple myeloma are resistant to CAR T-cell therapies. Moffitt researchers will also share findings on innovative approaches in myelodysplastic syndromes, chronic myelomonocytic leukemia and myeloproliferative neoplasms. For more information on how Moffitt advances care in hematologic malignancies, check out Moffitt.org/ASH and read the stories below.

Graphic of cancer cell with "featured at 66th ASH Annual Meeting" over the bottom

Hard-to-Treat Lymphoma Patients Benefit From New Immunotherapy

AZD0486 demonstrates high response rates in relapsed/refractory diffuse large B-cell lymphoma, including patients who failed CAR-T therapy

New Treatment Combination Improves Outcomes for Relapsed or Refractory Large B-Cell Lymphoma

Patients who received the mosunetuzumab-polatuzumab combination had a 78% response rate

Drug Aims To Improve Transplant Success for Myelofibrosis Patients

Study shows giving patients fedratinib is safe and could help reduce chance of relapse

Moffitt Study Explores Key Risk Factors To Better Personalize CAR T-Cell Therapy

The study analyzed ide-cel to help physicians intervene and reduce toxicities in multiple myeloma patients

Drug Offers New Option for Patients With Rare Blood Disorders in ‘No Man’s Land’

Fedratinib is approved to treat myelofibrosis and could be effective in myelodysplastic/myeloproliferative neoplasms

Largest Comprehensive Study Compares Efficacy of CAR T Products for Multiple Myeloma

Cilta-cel demonstrates greater effectiveness than ide-cel but carries higher toxicities, study finds

New Study Suggests Socioeconomic Status Affects Access to Leukemia Transplant, Not Survival

Researchers point to access to care as a major issue for people in lower socioeconomic brackets

Study Reveals Key Insights Between New Blood Condition and Lower-Risk Myelodysplastic Syndromes

High-risk CCUS patients by CHRS and CCRS risk stratification tools have similar characteristics and outcomes to patients with lower-risk MDS

Moffitt Study Finds New Genetic Clues to Resistance in Multiple Myeloma Treatments

Study reveals genetic markers that predict treatment resistance, offering potential for more personalized therapy plans

Moffitt Experts Conduct First Analysis on New Criteria for Chronic Myelomonocytic Leukemia

Study finds patients who were switched to a chronic myelomonocytic leukemia diagnosis based on the new criteria more so resembled myelodysplastic syndromes genetically.